The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Vascular Disrupting Agents Market, 2021-2030: Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Liver Cancer, Mesothelioma, Non-Small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer, Renal Pelvis and Ureter Cancer), Therapeutic Area (Hematological Malignancies, Solid Tumors), Molecules (Tubulin Binding Agents, Flavonoids and Ligand-Directed Agents), Therapy (Mono and Combination), Route of Administration (Oral, Intravenous), and Regions (North America, Europe, Asia-Pacific and RoW)

  • Lowest Price Guaranteed From USD 5,499

  • Published
    April 2021

  • Pages
    230

  • View Count
    114

Example Insights

Vascular-Disrupting-Agents-Market-Context Vascular-Disrupting-Agents-Market-Distribution-of-Developers-by-Size-and-Geography Vascular-Disrupting-Agents-Market-Distribution-by-Therapeutics-Area
Vascular-Disrupting-Agents-Market-Grant-Analysis Vascular-Disrupting-Agents-Market-Clinical-Reseasrch-Landscape Vascular-Disrupting-Agents-Market-Publication-Analysis
Vascular-Disrupting-Agents-Market-Regional-Distribution Vascular-Disrupting-Agents-Market-Future-Forecast  

 

Overview

According to the WHO, cancer is one of the leading causes of deaths worldwide, accounting for an estimated 10 million mortalities in 2020, which are projected to reach 13 million by 2030. Further, 90% of all diagnosed cancers are solid tumors  and a large number of the novel anticancer therapies are being developed for the treatment of these cancers. In the last five years, the United States Food and Drug Administration (USFDA) has approved more than 100 drugs for the treatment of different types of cancer. However, as the global population is gradually being exposed to a growing list of risk factors and cancer-causing agents, there is a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. Given the inherent nature of solid tumors to form rapidly growing masses of malignant cells, angiogenesis and adequate blood supply is critical to the survival of the bulk tumor population. Therefore, tumor vasculature continues to be an attractive and promising therapeutic target. Vascular disrupting agents (VDAs) are therapeutic interventions that target established tumor vasculature and thereby, disrupt blood flow to cancerous tissue. 

Presently, there are multiple small molecule VDAs, which have been / are being developed for the treatment of a variety of oncological conditions, including colorectal cancer, glioblastoma, hepatocellular carcinoma, lung cancer, melanoma and ovarian cancer. Moreover, combination therapies, involving VDAs and conventional chemotherapy, radiation therapy and radioimmunotherapy, have demonstrated excellent clinical responses in multiple animal models. It is worth noting that the R&D efforts in this field are being supported by the National Institutes of Health, accounting for USD 95 million in research grants disbursed since 2016. Driven by encouraging clinical research, this niche, but emerging domain, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The ‘Vascular Disrupting Agents Market, 2021-2030: Distribution by Target Indications (Chemotherapy-Induced Neutropenia, Glioblastoma, Hepatocellular Carcinoma, Malignant Pleural Mesothelioma,  Non-Small Cell Lung Cancer, Prostate Cancer, Recurrent Platinum Resistant Ovarian Cancer, Transitional Cell Cancer of Renal Pelvis and Ureter),  Therapeutic Area (Hematological Malignancies, Solid Tumors and Other Therapeutic Areas), Type of Molecule (Small Molecule (Tubulin Binding Agents and Flavonoids) and Ligand-Directed Agents) and Ligand-Directed Agents), Type of Therapy (Monotherapy, Combination Therapy And Both), Route of Administration (Oral, Intravenous), and  Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ report features an extensive study of the current and future potential of vascular disrupting agents, being developed for the treatment of various types of cancer. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes:

  • A detailed review of the current market landscape of vascular disrupting agents, including information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of product candidates, therapeutic area (hematological malignancies, solid tumors and others), target indication(s), type of molecule (small molecule (tubulin binding agents and flavonoids), and ligand directed agents), type of therapy (monotherapy, combination therapy and others) and route of administration (oral, intravenous and others). In addition, it presents a list of companies developing vascular disrupting agents and analysis based on year of establishment, company size and location of headquarters. 
  • Detailed profiles of the prominent players in this domain (shortlisted on the basis of number of vascular disrupting agents in development pipeline). Each profile features a brief overview of the company, its financial information (if available), detailed description (including information on the type of drug, current status of development, target indications, mode of action and type of therapy) of their respective lead drug candidates, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various vascular disrupting agents, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus and key indications.
  • A detailed review of more than 750 peer-reviewed, scientific articles related to research on vascular disrupting agents, which have been published during the period, 2016 - January 2021. The publications have been analyzed to highlight the trends across year of publication, emerging focus areas, popular keywords, key indications, key therapeutic areas, key research journals and popular authors. 
  • An in-depth analysis of grants awarded to various research institutes for the projects related to vascular disrupting agents, in the period between 2016 and January 2021, on the basis of parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A list of key opinion leaders (KOLs) within this domain, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with vascular disrupting agents, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target indications (chemotherapy-induced neutropenia, glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma,  non-small cell lung cancer, prostate cancer, recurrent platinum resistant ovarian cancer, transitional cell cancer of renal pelvis and ureter), [B] therapeutic area (hematological malignancies, solid tumors and other therapeutic areas), [C] type of molecule (small molecule and ligand-directed agents), [D] type of therapy (monotherapy, combination therapy and both), [E] route of administration (oral, intravenous), and [F] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Question Answered

  • Who are the leading industry and non-industry players in this market?
  • Which cancer indications can be treated with vascular disrupting agents?
  • Which geographies are the most active in conducting clinical trials on vascular disrupting agents?
  • What is the focus area of the research activities ongoing in this domain?
  • Which are the leading administering institute centers supporting the research related to this domain?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of vascular disrupting agent market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that provides an overview of the vascular disrupting agents. It includes an elaborate discussion on the role of vascular disrupting agents in the treatment of various tumors and the types of vascular disrupting agents (small molecules- flavonoids, tubulin binding agents, and ligand directed agents). In addition, it highlights the various challenges associated with the use of vascular disrupting agents and futuristic approach of adopting vascular disrupting agents in non-oncological indications. 

Chapter 4 features an overview of the current market landscape of vascular disrupting agents, providing information on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of product candidates, therapeutic area (hematological malignancies, solid tumors and others), target indication(s), type of molecule (small molecule (tubulin binding agents and flavonoids), and ligand directed agents), type of therapy (monotherapy, combination therapy and others) and route of administration (oral, intravenous and others). Further, the chapter provides information on the drug developer, along with an analysis based on year of establishment, company size and location of headquarters.

Chapter 5 includes elaborate profiles of prominent players engaged in the development of vascular disrupting agents (shortlisted on the basis of number of molecules in the pipeline). Each profile features a brief overview of the company, its financial information (if available), detailed description (including information on the type of drug, current status of development, target indications, mode of action and type of therapy) of their respective lead drug candidates, recent developments and an informed future outlook.

Chapter 6 provides a detailed analysis of completed, ongoing and planned clinical studies of various vascular disrupting agents, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of molecule, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus and key indications.

Chapter 7 provides information on the publications that we came across during our research on vascular disrupting agents. It also highlights the key trends across publications, based on year of publication, emerging focus areas, popular keywords, key indications, key therapeutic areas, key research journals and popular authors.

Chapter 8 provides an in-depth analysis of grants awarded to research institutes for the projects related to vascular disrupting agents, in the period between 2016 and January 2021, on the basis of some relevant parameters, such as year of award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, popular NIH departments, and type of recipient organization, while highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.

Chapter 9 provides an analysis of KOLs engaged in research activities related to vascular disrupting agents. It features a list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features schematic world map representations, highlighting the geographical locations of eminent scientists. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criterion, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Chapter 10 features a detailed market forecast of the likely growth of vascular disrupting agents till the year 2030. We have provided inputs on the likely distribution of the current and forecasted opportunity across [A] target indications (chemotherapy-induced neutropenia, glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma,  non-small cell lung cancer, prostate cancer, recurrent platinum resistant ovarian cancer, transitional cell cancer of renal pelvis and ureter), [B] therapeutic area (hematological malignancies, solid tumors and other therapeutic areas), [C] type of molecule (small molecule and ligand-directed agents), [D] type of therapy (monotherapy, combination therapy and both), [E] route of administration (oral, intravenous), and [F] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World).

Chapter 11 is a summary of the overall report. It presents the key takeaways and offers our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Vascular Disrupting Agents
3.2.1. Mechanism of Action of Vascular Disrupting Agents
3.3 Types of Vascular Disrupting Agents 
3.3.1. Small Molecule Vascular Disrupting Agents 
3.3.1.1. Tubulin Binding Agents
3.3.1.2. Flavonoids
3.3.2. Ligand Directed Vascular Disrupting Agents 
3.4. Benefits of Vascular Disrupting Agents
3.5. Challenges Associated with Vascular Disrupting Agents 
3.6. Future Perspectives

4. VASCULAR DISRUPTING AGENTS MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vascular Disrupting Agents: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Target Disease Indication
4.2.4. Analysis by Phase of Development and Target Disease Indication
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Target Disease Indication and Type of Molecule 
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Potential Combination Therapeutics

4.3. Vascular Disrupting Agents: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Drug Candidates

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Company Overview
5.2.2. Drug Portfolio: Vascular Disrupting Agents
5.2.2.1. Drug Profile: NGR-TNF

5.2.3. Recent Developments and Future Outlook

5.3. Avid Bioservices
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Drug Portfolio: Vascular Disrupting Agents
5.3.3.1. Drug Profile: Bavituximab

5.3.4. Recent Developments and Future Outlook

5.4. Bionomics
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Drug Portfolio: Vascular Disrupting Agents
5.4.3.1. Drug Profile: BNC105

5.4.4. Recent Developments and Future Outlook

5.5. Mateon Therapeutics
5.5.1. Company Overview
5.5.2. Drug Portfolio: Vascular Disrupting Agents
5.5.2.1. Drug Profile: CA4P
5.5.2.2. Drug Profile: OXi4503

5.5.3. Recent Developments and Future Outlook

5.6. Myrexis
5.6.1. Company Overview
5.6.2. Drug Portfolio: Vascular Disrupting Agents
5.6.2.1. Drug Profile: MPC-6827

5.6.3. Recent Developments and Future Outlook

5.7. VBL Therapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Drug Portfolio: Vascular Disrupting Agents
5.7.3.1. Drug Profile: VB-111

5.7.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Vascular Disrupting Agents: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Trial Status
6.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
6.3.4. Analysis by Trial Phase
6.3.5. Analysis by Trial Phase and Number of Patients Enrolled 
6.3.6. Geographical Analysis by Number of Clinical Trials
6.3.7. Geographical Analysis by Number of Patients Enrolled
6.3.8. Analysis by Study Design
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Drug Molecule
6.3.11. Analysis by Key Indications
6.3.12. Analysis by Type of Sponsor / Collaborator
6.3.13. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.14. Most Active Non-Industry Players: Analysis by Number of Registered Trials

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Vascular Disrupting Agents: List of Recent Publications
7.3.1. Analysis by Year of Publication
7.3.2. Emerging Focus Areas
7.3.3. Analysis by Popular Keywords
7.3.4. Analysis by Target Disease Indications
7.3.5. Analysis by Therapeutic Area
7.3.6. Popular Journals: Analysis by Number of Publications
7.3.7. Popular Journals: Analysis of Journal Impact Factor
7.3.8. Most Popular Authors: Analysis by Number of Publications

8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Vascular Disrupting agents: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Activity Code
8.3.8. Word Cloud Analysis: Emerging Focus Areas
8.3.9. Popular Recipient Organizations: Analysis by Number of Grants
8.3.10. Prominent Program Officers: Analysis by Number of Grants
8.3.11. Regional Distribution of Recipient Organizations

9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Methodology
9.3. Principal Investigators of Vascular Disrupting Agents Focused Clinical Trials 
9.3.1. Geographical Distribution of KOLs
9.3.2. Analysis by Type of Organization (KOL Affiliation) 
9.3.3. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
9.4. Prominent Key Opinion Leaders (KOLs)
9.5. KOL Benchmarking: Roots Analysis versus Third-Party Scoring (ResearchGate Score)
9.6. Profiles of Most Active KOLs
9.6.1. KOL Profile: KOL A 
9.6.2. KOL Profile: KOL B 
9.6.3. KOL Profile: KOL C 
9.6.4. KOL Profile: KOL D 
9.6.5. KOL Profile: KOL E 
9.6.6. KOL Profile: KOL F 

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Overall Vascular Disrupting Agents Market, 2021-2030
10.4.1. Vascular Disrupting Agents Market: Distribution by Target Indication
10.4.2. Vascular Disrupting Agents Market: Distribution by Therapeutic Area
10.4.3. Vascular Disrupting Agents Market: Distribution by Type of Molecule
10.4.4. Vascular Disrupting Agents Market: Distribution by Type of Therapy
10.4.5. Vascular Disrupting Agents Market: Distribution by Route of Administration
10.4.6. Vascular Disrupting Agents Market: Distribution by Geography
10.4.7. Product-wise Sales Forecast
10.4.7.1. Bavituximab (Avid Bioservices)
10.4.7.1.1. Target Patient Population
10.4.7.1.2. Sales Forecast (USD Million)
10.4.7.1.3. Net Present Value (USD Million)
10.4.7.1.4. Value Creation Analysis

10.4.7.2. Icaritin (Beijing Shenogen Biomedical)
10.4.7.2.1. Target Patient Population
10.4.7.2.2. Sales Forecast (USD Million)
10.4.7.2.3. Net Present Value (USD Million)
10.4.7.2.4. Value Creation Analysis

10.4.7.3. NGR-TNF (AGC Biologics)
10.4.7.3.1. Target Patient Population
10.4.7.3.2. Sales Forecast (USD Million)
10.4.7.3.3. Net Present Value (USD Million)
10.4.7.3.4. Value Creation Analysis

10.4.7.4. Padeliporfin (Steba biotech)
10.4.7.4.1. Target Patient Population
10.4.7.4.2. Sales Forecast (USD Million)
10.4.7.4.3. Net Present Value (USD Million)
10.4.7.4.4. Value Creation Analysis

10.4.7.5. Plinabulin (BeyondSpring Pharmaceuticals)
10.4.7.5.1. Target Patient Population
10.4.7.5.2. Sales Forecast (USD Million)
10.4.7.5.3. Net Present Value (USD Million)
10.4.7.5.4. Value Creation Analysis

10.4.7.6. VB-111 (VBL Therapeutics)
10.4.7.6.1. Target Patient Population
10.4.7.6.2. Sales Forecast (USD Million)
10.4.7.6.3. Net Present Value (USD Million)
10.4.7.6.4. Value Creation Analysis

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Vascular Disrupting Agents: Mechanism of Action on Tumor Cells
Figure 3.2 Types of Vascular Disrupting Agents
Figure 4.1 Vascular Disrupting Agents: Distribution by Phase of Development
Figure 4.2 Vascular Disrupting Agents: Distribution by Therapeutic Area
Figure 4.3 Vascular Disrupting Agents: Distribution by Target Disease Indication
Figure 4.4 Vascular Disrupting Agents: Distribution by Phase of Development and Target Disease Indication
Figure 4.5 Vascular Disrupting Agents: Distribution by Type of Molecule
Figure 4.6 Vascular Disrupting Agents: Distribution by Target Disease Indication and Type of Molecule
Figure 4.7 Vascular Disrupting Agents: Distribution by Type of Therapy
Figure 4.8 Vascular Disrupting Agents: Distribution by Route of Administration
Figure 4.9 Vascular Disrupting Agents: Distribution by Potential Combination Therapeutics
Figure 4.10 Vascular Disrupting Agent Developers: Distribution by Year of Establishment
Figure 4.11 Vascular Disrupting Agent Developers: Distribution by Company Size
Figure 4.12 Vascular Disrupting Agent Developers: Distribution by Location of Headquarters
Figure 4.13 Leading Players: Distribution by Number of Drug Candidates
Figure 5.1 Avid Bioservices: Annual Revenues, 2016-Q1 2021 (USD Million)
Figure 5.2 Bionomics: Annual Revenues, 2016-2020 (USD Million)
Figure 5.3 VBL Therapeutics: Annual Revenues, 2017-2020 (USD Million)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2001-2021 (till January)
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2021 (till January)
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.6 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Figure 6.7 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 6.8 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
Figure 6.10 Word Cloud: Popular Keywords
Figure 6.11 Clinical Trial Analysis: Distribution by Drug Molecule
Figure 6.12 Clinical Trial Analysis: Benchmarking by Number of Trials across Popular Indications
Figure 6.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.14 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 6.15 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 7.1 Publication Analysis: Cumulative Year-wise Trend, 2016-2021 (till January)
Figure 7.2 Publication Analysis: Distribution by Key Focus Areas
Figure 7.3 Publication Analysis: Word Cloud of Study Titles
Figure 7.4 Key Indications: Distribution by Number of Published Studies
Figure 7.5 Key Therapeutic Areas: Distribution by Number of Published Studies
Figure 7.6 Popular Journals: Distribution by Number of Publications
Figure 7.7 Popular Journals: Distribution by Journal Impact Factor
Figure 7.8 Most Popular Authors: Distribution by Number of Publications
Figure 8.1 Grant Analysis: Cumulative Year-Wise Trend of Grants, 2016-2021 (till January)
Figure 8.2 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Figure 8.3 Grant Analysis: Distribution by Administering Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
Figure 8.7 Grant Analysis: Distribution by Activity Code
Figure 8.8 Word Cloud: Emerging Focus Areas
Figure 8.9 Popular Recipient Organization: Distribution by Number of Grants
Figure 8.10 Prominent Program Officers: Distribution by Number of Grants
Figure 8.11 Regional Distribution of Recipient Organizations
Figure 9.1 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Figure 9.2 KOL Analysis: Distribution by Location of Organization
Figure 9.3 KOL Analysis: Leading Organizations (KOL Affiliation)
Figure 9.4 KOLs in North America
Figure 9.5 KOLs in Europe
Figure 9.6 KOLs in Asia-Pacific and Rest of the World
Figure 9.7 KOL Analysis: Dot-Plot of KOLs
Figure 9.8 KOL Analysis: Most Prominent KOLs
Figure 9.9 KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Figure 10.1 Global Vascular Disrupting Agents Market, 2021-2030
Figure 10.2 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Target Indication
Figure 10.3 Vascular Disrupting Agents Market for Chemotherapy-induced Neutropenia, 2021-2030 (USD Million)
Figure 10.4 Vascular Disrupting Agents Market for Glioblastoma, 2021-2030 (USD Million)
Figure 10.5 Vascular Disrupting Agents Market for Hepatocellular Carcinoma, 2021-2030 (USD Million)
Figure 10.6 Vascular Disrupting Agents Market for Malignant Pleural Mesothelioma, 2021-2030 (USD Million)
Figure 10.7 Vascular Disrupting Agents Market for Non-Small Cell Lung Cancer, 2021-2030 (USD Million)
Figure 10.8 Vascular Disrupting Agents Market for Prostate Cancer, 2021-2030 (USD Million)
Figure 10.9 Vascular Disrupting Agents Market for Recurrent Platinum Resistant Ovarian Cancer, 2021-2030 (USD Million)
Figure 10.10 Vascular Disrupting Agents Market for Transitional Cell Cancer of Renal Pelvis and Ureter, 2021-2030 (USD Million)
Figure 10.11 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Therapeutic Area
Figure 10.12 Vascular Disrupting Agents Market for Hematological Malignancies, 2021-2030 (USD Million)
Figure 10.13 Vascular Disrupting Agents Market for Solid Tumors, 2021-2030 (USD Million)
Figure 10.14 Vascular Disrupting Agents Market for Other Therapeutic Areas, 2021-2030 (USD Million)
Figure 10.15 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Type of Molecule
Figure 10.16 Vascular Disrupting Agents Market for Small Molecules, 2021-2030 (USD Million)
Figure 10.17 Vascular Disrupting Agents Market for Ligand Directed Agents, 2021-2030 (USD Million)
Figure 10.18 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Type of Therapy
Figure 10.19 Vascular Disrupting Agents Market for Monotherapy, 2021-2030 (USD Million)
Figure 10.20 Vascular Disrupting Agents Market for Combination Therapy, 2021-2030 (USD Million)
Figure 10.21 Vascular Disrupting Agents Market for Both, Monotherapy and Combination Therapy, 2021-2030 (USD Million)
Figure 10.22 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Route of Administration
Figure 10.23 Vascular Disrupting Agents Market for Oral Therapies, 2021-2030 (USD Million)
Figure 10.24 Vascular Disrupting Agents Market for Intravenous Therapies, 2021-2030 (USD Million)
Figure 10.25 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Geography
Figure 10.26 Vascular Disrupting Agents Market in North America, 2021-2030 (USD Million)
Figure 10.27 Vascular Disrupting Agents Market in Europe, 2021-2030 (USD Million)
Figure 10.28 Vascular Disrupting Agents Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 10.29 Vascular Disrupting Agents Market in Latin America, 2021-2030 (USD Million)
Figure 10.30 Vascular Disrupting Agents Market in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.31 Vascular Disrupting Agents Market in Rest of the World, 2021-2030 (USD Million)
Figure 10.32 Bavituximab: Target Patient Population
Figure 10.33 Bavituximab Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 10.34 Icaritin: Target Patient Population
Figure 10.35 Icaritin Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 10.36 NGR-TNF: Target Patient Population
Figure 10.37 NGR-TNF Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 10.38 Padeliporfin: Target Patient Population
Figure 10.39 Padeliporfin Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 10.40 Plinabulin: Target Patient Population
Figure 10.41 Plinabulin Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 10.42 VB-111: Target Patient Population
Figure 10.43 VB-111 Sales Forecast (Till 2030), Base Scenario (USD Million)
Figure 11.1 Concluding Remarks: Current Market Landscape
Figure 11.2 Concluding Remarks: Clinical Trial Analysis
Figure 11.3 Concluding Remarks:
Figure 11.4 Concluding Remarks: Publication Analysis
Figure 11.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Vascular Disrupting Agents: Information on Phase of Development, Target Disease Indication(s), Therapeutic Area and NCT number
Table 4.2 Vascular Disrupting Agents: Information on Route of Administration, Type of Molecule, Type of Therapy and Combination Therapeutics
Table 4.3 Vascular Disrupting Agents: List of Discontinued Drugs
Table 4.4 Vascular Disrupting Agents: Developer Landscape
Table 5.1 Vascular Disrupting Agents: List of Profiled Companies
Table 5.2 AGC Biologics: Company Snapshot
Table 5.3 Drug Profile: NGR-TNF
Table 5.4 Recent Developments and Future Outlook
Table 5.5 Avid Bioservices: Company Snapshot
Table 5.6 Drug Profile: Bavituximab
Table 5.7 Recent Developments and Future Outlook
Table 5.8 Bionomics: Company Snapshot
Table 5.9 Drug Profile: BNC105
Table 5.10 Recent Developments and Future Outlook
Table 5.11 Mateon Therapeutics: Company Snapshot
Table 5.12 Drug Profile: CA4P
Table 5.13 Drug Profile: OXi4503
Table 5.14 Recent Developments and Future Outlook
Table 5.15 Myrexis: Company Snapshot
Table 5.16 Drug Profile: MPC-6827
Table 5.17 Recent Developments and Future Outlook
Table 5.18 VBL Therapeutics: Company Snapshot
Table 5.19 Drug Profile: VB-111
Table 5.20 Recent Developments and Future Outlook
Table 7.1 Vascular Disrupting Agents: List of Recent Publications, 2016-January 2021
Table 9.1 Vascular Disrupting Agents: List of Principal Investigators
Table 9.2 KOLs: Roots Analysis (RA) Proprietary Scoring System
Table 9.3 KOL Profile: A
Table 9.4 KOL Profile: B
Table 9.5 KOL Profile: C
Table 9.6 KOL Profile: D
Table 9.7 KOL Profile: E
Table 9.8 KOL Profile: F
Table 10.1 Vascular Disrupting Agents: Expected Launch Years of Advanced Stage Drug Candidates
Table 10.2 Bavituximab: Target Patient Population
Table 10.3 Bavituximab: Net Present Value (USD Million)
Table 10.4 Icaritin: Target Patient Population
Table 10.5 Icaritin: Net Present Value (USD Million)
Table 10.6 NGR-TNF: Target Patient Population
Table 10.7 NGR-TNF: Net Present Value (USD Million)
Table 10.8 Padeliporfin: Target Patient Population
Table 10.9 Padeliporfin: Net Present Value (USD Million)
Table 10.10 Plinabulin: Target Patient Population
Table 10.11 Plinabulin: Net Present Value (USD Million)
Table 10.12 VB-111: Target Patient Population
Table 10.13 VB-111: Net Present Value (USD Million)
Table 12.1 Vascular Disrupting Agents: Distribution by Phase of Development
Table 12.2 Vascular Disrupting Agents: Distribution by Therapeutic Area
Table 12.3 Vascular Disrupting Agents: Distribution by Target Disease Indication
Table 12.4 Vascular Disrupting Agents: Distribution by Phase of Development and Target Disease Indication
Table 12.5 Vascular Disrupting Agents: Distribution by Type of Molecule
Table 12.6 Vascular Disrupting Agents: Distribution by Target Disease Indication and Type of Molecule
Table 12.7 Vascular Disrupting Agents: Distribution by Type of Therapy
Table 12.8 Vascular Disrupting Agents: Distribution by Route of Administration
Table 12.9 Vascular Disrupting Agents: Distribution by Potential Combination Therapeutics
Table 12.10 Vascular Disrupting Agent Developers: Distribution by Year of Establishment
Table 12.11 Vascular Disrupting Agent Developers: Distribution by Company Size
Table 12.12 Vascular Disrupting Agent Developers: Distribution by Location of Headquarters
Table 12.13 Leading Players: Distribution by Number of Drug Candidates
Table 12.14 Avid Bioservices: Annual Revenues, 2016- Q1 2021 (USD Million)
Table 12.15 Bionomics: Annual Revenues, 2016-2020 (USD Million)
Table 12.16 VBL Therapeutics: Annual Revenues, 2017-2020 (USD Million)
Table 12.17 Clinical Trial Analysis: Distribution by Trial Status
Table 12.18 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2001-2021 (till January)
Table 12.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2021 (till January)
Table 12.20 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled
Table 12.21 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.22 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 12.23 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 12.24 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 12.25 Clinical Trial Analysis: Distribution by Study Design
Table 12.26 Clinical Trial Analysis: Distribution by Drug Molecule
Table 12.27 Clinical Trial Analysis: Benchmarking by Number of Trials across Popular Indications
Table 12.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.29 Most Active Industry Players: Distribution by Number of Registered Trials
Table 12.30 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 12.31 Publication Analysis: Cumulative Year-wise Trend, 2016- 2021 (till January)
Table 12.32 Publication Analysis: Distribution by Key Focus Areas
Table 12.33 Key Indications: Distribution byNumber of Published Studies)
Table 12.34 Key Therapeutic Areas (Distribution by Number of Published Studies)
Table 12.35 Popular Journals: Distribution by Number of Publications
Table 12.36 Popular Journals: Distribution by Journal Impact Factor
Table 12.37 Most Popular Authors: Distribution by Number of Publications
Table 12.38 Grant Analysis: Cumulative Year-Wise Trend of Grants, 2016-2021 (till January)
Table 12.39 Grant Analysis: Distribution by Amount Awarded (USD Million), 2016-2021
Table 12.40 Grant Analysis: Distribution by Administering Institute Center
Table 12.41 Grant Analysis: Distribution by Support Period
Table 12.42 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 12.43 Grant Analysis: Distribution by Type of Grant Application
Table 12.44 Grant Analysis: Distribution by Activity Code
Table 12.45 Popular Recipient Organizations: Distribution by Number of Grants
Table 12.46 Prominent Program Officers: Distribution by Number of Grants
Table 12.47 Regional Distribution of Recipient Organizations
Table 12.48 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Table 12.49 KOL Analysis: Distribution by Location of Organization
Table 12.50 KOL Analysis: Leading Organizations (KOL Affiliation)
Table 12.51 KOLs in North America
Table 12.52 KOLs in Europe
Table 12.53 KOLs in Asia-Pacific and Rest of the World
Table 12.54 KOL Analysis: Most Prominent Key Opinion Leaders
Table 12.55 KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Table 12.56 Global Vascular Disrupting Agents Market, 2021-2030
Table 12.57 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Target Indication
Table 12.58 Vascular Disrupting Agents Market for Chemotherapy-induced Neutropenia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.59 Vascular Disrupting Agents Market for Glioblastoma, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.60 Vascular Disrupting Agents Market for Hepatocellular Carcinoma, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.61 Vascular Disrupting Agents Market for Malignant Pleural Mesothelioma, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.62 Vascular Disrupting Agents Market for Non-Small Cell Lung Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.63 Vascular Disrupting Agents Market for Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.64 Vascular Disrupting Agents Market for Recurrent Platinum Resistant Ovarian Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.65 Vascular Disrupting Agents Market for Transitional Cell Cancer of Renal Pelvis and Ureter, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.66 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Therapeutic Area
Table 12.67 Vascular Disrupting Agents Market for Hematological Malignancies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.68 Vascular Disrupting Agents Market for Solid Tumors, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.69 Vascular Disrupting Agents Market for Other Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.70 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Type of Molecule
Table 12.71 Vascular Disrupting Agents Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.72 Vascular Disrupting Agents Market for Ligand Directed Agents, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.73 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Type of Therapy
Table 12.74 Vascular Disrupting Agents Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.75 Vascular Disrupting Agents Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.76 Vascular Disrupting Agents Market for Both, Monotherapy and Combination Therapy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.77 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Route of Administration
Table 12.78 Vascular Disrupting Agents Market for Oral Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.79 Vascular Disrupting Agents Market for Intravenous Therapies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.80 Global Vascular Disrupting Agents Market, 2021 and 2030: Distribution by Geography
Table 12.81 Vascular Disrupting Agents Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.82 Vascular Disrupting Agents Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.83 Vascular Disrupting Agents Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.84 Vascular Disrupting Agents Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.85 Vascular Disrupting Agents Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.86 Vascular Disrupting Agents Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.87 Bavituximab: Target Patient Population
Table 12.88 Bavituximab Sales Forecast (Till 2030), Base Scenario (USD Million)
Table 12.89 Icaritin: Target Patient Population
Table 12.90 Icaritin Sales Forecast (Till 2030), Base Scenario (USD Million)
Table 12.91 NGR-hTNF: Target Patient Population
Table 12.92 NGR-hTNF Sales Forecast (Till 2030), Base Scenario (USD Million)
Table 12.93 Padeliporfin: Target Patient Population
Table 12.94 Padeliporfin Sales Forecast (Till 2030), Base Scenario (USD Million)
Table 12.95 Plinabulin: Target Patient Population
Table 12.96 Plinabulin Sales Forecast (Till 2030), Base Scenario (USD Million)
Table 12.97 VB-111: Target Patient Population
Table 12.98 VB-111 Sales Forecast (Till 2030), Base Scenario (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. AbbVie
  2. Abramson Cancer Center
  3. Academy of Military Medical Sciences
  4. AIDS Malignancy Consortium
  5. Amgen
  6. Anhui Provincial Hospital
  7. Argonaut Manufacturing Services
  8. Asan Medical Center
  9. Asian Myeloid Working Group
  10. Atlantic Urology Clinics
  11. Austin Health
  12. Avid Bioservices (formerly known as Peregrine Pharmaceuticals)
  13. Barbara Ann Karmanos Cancer Institute
  14. Basilea Pharmaceutica
  15. Beijing Cancer Hospital
  16. Beijing Chaoyang Hospital
  17. Beijing Shenogen Pharmaceutical
  18. BeyondSpring
  19. Bionomics
  20. Brigham and Women's Hospital
  21. Cancer Treatment Centers of America
  22. Carle Cancer Institute
  23. Case Comprehensive Cancer Center (Case CCC)
  24. Case Western Reserve University
  25. Celgene (acquired by Bristol Myers Squibb)
  26. China University of Petroleum-Beijing (CUP)
  27. Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
  28. Chong Kun Dang Pharmaceutical
  29. Cleveland Clinic
  30. Columbia University Health Sciences
  31. Dana-Farber Cancer Institute
  32. Dartmouth College
  33. Dartmouth-Hitchcock Medical Center
  34. Dresden University of Technology (TUD)
  35. Duke Cancer Institute
  36. Duke University
  37. Emory University
  38. EpiCept
  39. Fennec Pharmaceuticals
  40. First Affiliated Hospital of Harbin Medical University
  41. First Affiliated Hospital of Xi'an Jiaotong University (formerly known as the The First Affiliated Hospital of Xi’an Medical University)
  42. Fox Chase Cancer Center
  43. Froedtert & the Medical College of Wisconsin
  44. Fudan University
  45. Fudan University Shanghai Cancer Center (FUSCC)
  46. Fujian Provincial Cancer Hospital
  47. Guangxi University
  48. H. Lee Moffitt Cancer Center and Research Institute
  49. Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut
  50. Henan Provincial People's Hospital
  51. Henry Ford Health System
  52. Hospital Universitario Clínico San Carlos
  53. Hunan Cancer Hospital
  54. Iceni Pharmaceuticals
  55. Incanthera
  56. Institute of Hematology and Blood Diseases Hospital (IH)
  57. Jilin Provincial Cancer Hospital (JPCH)
  58. Jinzhou Medical University
  59. Kepler University Hospital
  60. Krankenhaus der Barmherzigen Schwestern
  61. Linyi Cancer Hospital
  62. Madrigal Pharmaceuticals
  63. Marshfield Clinic Health System
  64. Massachusetts General Hospital
  65. Mateon Therapeutics
  66. Mayo Clinic
  67. MediciNova
  68. Memorial Sloan Kettering Cancer Center
  69. Millennium Pharmaceuticals
  70. Moffitt Cancer Center
  71. MolMed (acquired by AGC Biologics)
  72. Multiple Myeloma Research Consortium (MMRC)
  73. Myrexis
  74. Nanfang Hospital of Southern Medical University (NFYY)
  75. Nanjing Medical University
  76. Nanjing Sanhome Pharmaceutical
  77. NanoCarrier
  78. National Cancer Institute
  79. National University Hospital (NUH)
  80. NIH Clinical Center
  81. Northwell Health
  82. Northwestern University Feinberg School of Medicine
  83. Novartis
  84. O’Neal Comprehensive Care Center at UAB
  85. Ochsner Medical Center
  86. Oregon Health & Science University (OHSU)
  87. Paracelsus Medical University Salzburg
  88. Parc Taulí
  89. Parkview Cancer Institute
  90. Peking Union Medical College Hospital
  91. Peking University Health Science Center
  92. People’s Liberation Army (PLA) 81 Hospital
  93. PharmaMar
  94. Poznan University of Medical Sciences (PUMS)
  95. Premier Gynecologic Oncology
  96. Qilu Hospital of Shandong University
  97. Rankweil Hospital
  98. Ruijin Hospital
  99. Rutgers Cancer Institute of New Jersey
  100. Rutgers New Jersey Medical School
  101. San Raffaele Hospital
  102. Sanford Health
  103. Sanofi Genzyme
  104. Shanghai Changzheng Hospital
  105. Shanghai Jiao Tong University
  106. Shenyang Sixth People's Hospital
  107. Sichuan Industrial Institute of Antibiotics (SIIA)
  108. SP ZOZ Ministerstwa Spraw Wewnętrznych z Warmińsko – Mazurskim Centrum Onkologii
  109. St. Joseph Medical Center
  110. St. Luke's University Health Network (SLUHN)
  111. St. Vincent Gynecologic Oncology
  112. Steba biotech
  113. Sylvester Comprehensive Cancer Center
  114. SynCore Biotechnology
  115. Takeda
  116. Teva Pharmaceutical Industries
  117. Texas Oncology-Austin Central
  118. The First Affiliated Hospital of Anhui Medical University
  119. The First Affiliated Hospital with Nanjing Medical University
  120. The First Hospital of China Medical University
  121. The First Hospital of Jilin University
  122. The First People's Hospital of Foshan
  123. The Johns Hopkins Hospital
  124. The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)
  125. The Sixth Affiliated Hospital of Sun Yat-sen University
  126. The Third Xiangya Hospital of Central South University
  127. The University of Texas MD Anderson Cancer Center
  128. Tianjin Medical University Cancer Institute and Hospital (TMUCIH)
  129. Tongji Hospital
  130. UAB Division of GYN Oncology
  131. UAMS Myeloma Center
  132. UCLA Jonsson Comprehensive Cancer Center
  133. University College London
  134. University Hospital of Clermont-Ferrand
  135. University Hospital Würzburg
  136. University of Arizona Cancer Center
  137. University of Arkansas
  138. University of California, Irvine (UCI)
  139. University of Chicago
  140. University of Cincinnati
  141. University of Colorado Denver
  142. University of Illinois at Chicago
  143. University of Iowa
  144. University of Kansas Cancer Center
  145. University of Kentucky
  146. University of Minnesota
  147. University of New Mexico
  148. University Of North Carolina at Chapel Hill
  149. University of Texas Health Science Center
  150. University of Vermont
  151. University of Wisconsin
  152. UPMC Hillman Cancer Center
  153. UT Southwestern Medical Center
  154. VBL Therapeutics
  155. Virgen del Rocío University Hospital
  156. Wake Forest Baptist Medical Center
  157. Wake Forest School of Medicine
  158. West Penn Hospital
  159. Wilhelminenspital Vienna
  160. Wilmot Cancer Institute
  161. Wistar Institute
  162. Yunnan Provincial Hospital of Traditional Chinese Medicine
  163. Zhongshan Hospital, Fudan University

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com